Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
复制标题
DOI：
10.1007/s004320050319
复制
发表时间：
1999-10-01
影响因子：
3.6
通讯作者：
Schmiegel, W
中科院分区：
文献类型：
--
作者：
Graeven, U;Andre, N;Schmiegel, W
目的：血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）是肿瘤诱导血管生成的重要介质。我们检测了软组织肉瘤患者的血清VF、GF和bFGF水平，并将血清VEGF和bFGF水平与手术和组织学分级时的肿瘤状态相关联。材料与方法：18例健康对照者和85例软组织肉瘤患者入选本研究。根据手术时的肿瘤状态对患者进行分类。血清VEGF和bFGF水平也与组织学分级相关。通过酶联免疫吸附测定（Quantikine R&D Systems）测定VEGF和bFGF水平。结果：患者组血清VEGF和bFGF水平均显著升高（VEGF：580 pg/ml，bFbF：21 pg/ml，P = 0.0001）。最高浓度的血清VEGF和bFGF被发现与宏观肿瘤病变或G3组织学的患者。血清VEGF水平与肿瘤状态和分级具有统计学显著相关性（肿瘤状态P = 0.006，分级P = 0.0001）。结论：这项研究表明，术前血清VEGF和bFGF水平升高，可以检测到在大多数软组织肉瘤患者。与肿瘤质量和组织学分级的显着相关性表明，VEGF和bFGF在软组织肉瘤患者血清中的连续监测可能是一个有价值的肿瘤随访标志物。
Purpose: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been suggested to be important mediators for tumor-induced angiogenesis. We measured serum VF,GF and bFGF levels from patients with soft-tissue sarcomas and correlated serum VEGF and bFGF levels with tumor status at surgery and histological grading. Materials and methods: A group of 18 healthy controls and 85 patients with soft-tissue sarcoma were enrolled in this study. The patients were classified according to tumor status at surgery. Serum levels of VEGF and bFGF were also correlated with histological grading. VEGF and bFGF levels were determined by enzyme-linked immunosorbent assay (Quantikine R&D Systems). Results: Serum VEGF and bFGF levels were significantly elevated in the patient group (VEGF: 580pg/ml, bFbF: 21pg/ml, P = 0.0001). The highest concentrations of serum VEGF and bFGF were found in patients with macroscopic tumor lesions or G3 histology. Serum VEGF levels showed a statistically significant correlation with tumor status and grading (P = 0.006 for tumor status, P = 0.0001 for grading). Conclusions: This study reveals that elevated preoperative serum VEGF and bFGF levels can be detected in the majority of patients with soft-tissue sarcoma. The significant correlation with tumor mass and histological grading suggests that a consecutive monitoring of VEGF and bFGF in the serum of patients with soft-tissue sarcoma might be a valuable marker for tumor follow-up.